Search
Sulfadiazine
go.drugbank.com/drugs/DB00359ApprovedInvestigationalVet approvedOne of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseFosdenopterin
go.drugbank.com/drugs/DB16628ApprovedIn July 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended fosdenopterin be granted marketing authorization under exceptional circumstances for the treatment of patients … [A230088,A230593] In the past, management strategies for this disorder involved symptomatic and supportive treatment,[L32163] though efforts were made to develop a suitable exogenous replacement for the
Tralokinumab
go.drugbank.com/drugs/DB12169ApprovedInvestigationalTralokinumab was first approved for the treatment of atopic dermatitis by the EMA in June 2021, under the brand name Adtralza (Leo Pharma), and was subsequently approved in Canada in October 2021 and the
Categories: Agents for Dermatitis, Excluding CorticosteroidsCefixime
go.drugbank.com/drugs/DB00671ApprovedInvestigational[A263026] However, cefixime is not recommended as a first-line of treatment for uncomplicated urogenital, anorectal, or pharyngeal gonorrhea because cefixime does not provide the same bactericidal effect … [A262995,A262945,A262950] Specifically, cephalosporins inhibit penicillin-sensitive enzymes responsible for the final 3D structure of the bacterial cell wall which in turn inhibit bacterial cell wall peptidoglycan
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseStreptococcus pneumoniae type 3 capsular polysaccharide antigen
go.drugbank.com/drugs/DB10321ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Mixtures: PREVENAR 13 SUSPENSION FOR INJECTIONCeliprolol
go.drugbank.com/drugs/DB04846ApprovedInvestigationalWithdrawnCeliprolol is not approved for use by the FDA in the treatment of vascular Ehlers–Danlos syndrome. … Celiprolol is indicated for the management of mild to moderate hypertension and effort-induced angina pectoris.
Categories: Adrenergic beta-2 Receptor Agonists, Adrenergic beta-3 Receptor AgonistsLorlatinib
go.drugbank.com/drugs/DB12130ApprovedInvestigationalLorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018 … It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to
Clotrimazole
go.drugbank.com/drugs/DB00257ApprovedInvestigationalVet approvedThe minimal side effect profile of this drug and its uncomplicated metabolic profile have led it to gain widespread acceptance for the treatment of mycotic outbreaks such as vaginal yeast infections as
Categories: Antifungals for Topical Use, Antifungals for Dermatological UsePegulicianine
go.drugbank.com/drugs/DB18731ApprovedInvestigational[L50537] Pegulicianine (under the brand name Lumisight) was approved for use by the FDA in April 2024.[L50537,L50547] It received Fast Track and priority review for this indication.[L50547] … Pegulicianine is an optical imaging agent indicated for fluorescence imaging in patients with breast cancer.
Ammonia N-13
go.drugbank.com/drugs/DB09326ApprovedAmmonia N 13 Injection, USP is a positron emitting radiopharmaceutical that is used for diagnostic purposes in conjunction with positron emission tomography (PET) imaging. … Ammonia N 13 Injection, USP is used for imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease